

A FASTER* COUNTDOWN TO ONSET OF RELIEF WITH FLEXIBLE PRN DOSING**

PRN nasal symptom relief that starts working in 30 minutes^{1,8,*}



Introducing the first¹⁰ and only¹¹ OTC AH nasal spray⁹

STARTS WORKING FASTER ON THE FIRST DAY



For patients with allergic rhinitis, Astepro® Allergy provides nasal symptom relief that **starts working** in **30 minutes** and lasts up to 24 hours.^{1,8,9}

■ INS sprays can take up to 12 hours to provide relief and 3 to 14 days to reach maximum efficacy levels^{2-7,*}



Astepro delivers relief of **indoor and outdoor** allergy symptoms (nasal congestion, runny nose, itchy nose, and sneezing) without steroids or an additional decongestant.⁹

INS, intranasal steroid.

*INS onset based on various product information; time to maximum efficacy depends on the INS brand.

THE FREEDOM OF PRN DOSING

 Flexibility to dose PRN, once or twice a day versus leading allergy spray products that recommend daily dosing schedules that may not match patient usage behavior^{9,12,†}

Dosed PRN

1 TIME DAILY

R

2 TIME

With Astepro, many patients can achieve relief in just one dose a day, while having the flexibility to dose twice daily as needed⁹

For Astepro Allergy dosing instructions, see the Drug Facts label or page 6.

Many patients may use INS sprays incorrectly, reaching for them only when symptoms arise


- ◆ Of the nasal spray users (n=732) in a survey, conducted by Bayer[®], of patients taking medication for their allergies (N=1202)^{12,13}:
 - 42% said they administer INS sprays "some days and not others"
 - More than one-third reported administering a spray as soon as they experienced symptoms

Patient non-compliance with daily INS sprays dosing regimens can compromise efficacy¹³



POWERFUL ALLERGY SYMPTOM RELIEF PREVIOUSLY ONLY AVAILABLE BY PRESCRIPTION^{9,14-16}

◆ Astepro® Allergy is proven to relieve nasal congestion the most bothersome symptom for many allergy sufferers —as well as runny nose, itchy nose, and sneezing^{17,18}



Results of a 2-week, placebo-controlled, double-blind study comparing azelastine HCI 0.15% nasal spray, 2 sprays per nostril once daily, with placebo in patients with SAR (n=266 for patients receiving Astepro and n=266 for patients receiving placebo). The study was conducted in the United States during Texas Mountain Cedar season. The primary efficacy variable was change from baseline in 12-hour reflective TNSS over the entire 2 weeks of treatment. TNSS consisted of nasal congestion, itchy nose, runny nose, and sneezing, scored on a 4-point (0-3) scale with a maximum possible daily score of 24.18

ASTEPRO ALLERGY IS THE FIRST® AND ONLY" ANTIHISTAMINE **NASAL SPRAY**

 Astepro is different than intranasal steroid (INS) sprays; the checklist below can help you explain its different characteristics to your patients

See How Astepro Compares to INS Sprays		
Comparison based on selected attributes. Always remember to read the label.	ASTEPRO® ALLERGY	INS Sprays
Flexible PRN dosing ^{9,21-23}	⊘	
Starts working in 30 minutes 1-8,4	⊘	
Steroid free ^{3,6,9,24}	⊘	
Decongestant free 3,6,9,24	⊘	✓
Available OTC at full Rx strength ^{3,6,9,21-24}	⊘	~

SAR, seasonal allergic rhinitis; TNSS, Total Nasal Symptom Score.

4

ASTEPRO® ALLERGY SAFETY PROFILE AND DOSING

- Astepro is a **steroid-free** allergy relief option for patients who want to avoid ongoing steroid use⁹
- Astepro has a well-established safety profile with more than 12 years in clinical use as a prescription product⁹
 - In clinical trials, drowsiness was observed in less than 4% of patients taking Astepro^{14,25}
 - Astepro does not have a warning regarding pediatric growth suppression in its Drug Facts Label⁹

Dosing Instructions9

Adults and children 12 years and older

- Once daily: use 2 sprays in each nostril; OR
- Twice daily: use 1 or 2 sprays in each nostril every 12 hours
- **◆ Do not use more than 4 sprays** in each nostril in a 24 hour period


Children 6 years to 11 years

- ◀ An adult should supervise use
- ◀ 1 spray in each nostril every 12 hours
- ◆ Do not use more than 2 sprays in each nostril in a 24 hour period. Do not use for children under 6 years

AVAILABLE IN THE FOLLOWING METERED SPRAY OPTIONS



Approved for adults and children age 6+



Astepro:

22, 60, 120, 200 metered sprays; 2 x 120, 3 x 120



Children's Astepro:

60 and 120 metered sprays







RECOMMEND PRN NASAL SYMPTOM RELIEF THAT STARTS WORKING IN 30 MINUTES^{1,8}

- Astepro® Allergy—the first¹⁰ and only¹¹ OTC AH nasal spray°—
 is different than intranasal steroid (INS) sprays
 - Relief starts in 30 minutes,* while INS sprays take hours to start to provide relief and can take between 3 and 14 days to reach maximum efficacy levels^{1-8,†}
 - Flexibility to dose PRN, versus leading allergy spray products that recommend daily dosing schedules that may not match patient usage behavior^{9,12,†}
- Powerful, steroid-free nasal symptom relief for up to 24 hours⁹

*On day 1, compared with steroid allergy sprays.

†INS onset based on various product information; time to maximum efficacy depends on the INS brand.

References: 1. Data on file. Bayer. Study 20877. Onset of action. 2. Flonase® website. Accessed July 23, 2021. https://www.flonase.com/faqs/ 3. Flonase®. Prescribing Information. GlaxoSmithKline; 2019. 4. GSK health partner website. Accessed September 17, 2021. https://www.gskhealthpartner.com/en-us/respiratory-health/brands/flonase-products/flonase/dosing-administration-flonase-allergy-relief/ 5. Nasacort® website. Accessed September 17, 2021. https://www.nasacort.com/allergy-nasal-spray-nasacort-faqs/ 6. Nasacort® AQ-rescribing information. Sanofi-avents U.S. LLC; 2008. 7. Rhinocort website. Accessed November 11, 2021. https://www.rhinocort.com/allergy-nasal-spray/adult-otc-spray 8. Shah S, Berger W, Lumry W, La Force C, Wheeler W, Sacks H. Efficacy and safety of azelastine 0.15% nasal spray and azelastine 0.10% nasal spray in patients with seasonal allergic rhinitis. Allergy Asthma Proc. 2009;30(6):628-633. doi:10.2500/aap.2009.30.3296 9. NDA 213872. 10. FDA approves a nasal antihistamine for nonprescription use. Approval is a first-in-class and was enabled by the prescription to nonprescription switch process. News release. FDA; June 17, 2021. Accessed October 7, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-nasal-antihistamine-nonprescription-use 11. Data on file. Bayer. IRI data. Only OTC AH. 12. Data on file. Bayer. Habits and practices. 13. Ortiz G, Knutdtson M. Counseling patients on the use of intransal steroids in allergic rhinitis management. Consultant. 2017;57(6):328-334. 14. Astepro-®. Prescribing information. Meda Pharmaceuticals Inc; 2018. 15. US Department of Health and Human Services. Pediatric Postmarketing Pharmacovigilance and Drug Utilization Review. November 3, 2016. Accessed October 28, 2021. https://www.fda.gov/media/100100/download16. Astelin. Prescribing information. Meda Pharmaceuticals Inc; 2014. 17. Stewart M, Ferguson BJ, Fromer L. Epidemiology and burden of nasal congestion. Int J Gen Med. 2010;3:37-45. 18. van Bavel J, Howland WC, Amar NJ, Wheeler W, Sa

Bayer and the Bayer Cross are registered trademarks of Bayer. ASTEPRO is a Viatris Company trademark. Used under license. All third party trademarks used herein are registered trademarks of their respective owners. © 2021 Bayer December 2021 PP-CLA-BASE-US-14178

